NAYA: Multiplikator P/S NAYA Biosciences Corp
NAYA Biosciences is accelerating the search for cancer therapies by utilizing robotic cell analysis systems. High R&D expenditures and stringent FDA oversight, combined with unique antibody patents, create significant barriers to entry for competitors. The company's price/sales multiple, which currently stands at 0.30, demonstrates that valuation is dependent on clinical trial results and investment inflows.
Rincian analitis perusahaan NAYA Bio (NAYA)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi NAYA Biosciences|NAYA - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas NAYA Biosciences Corp|NAYA - Gunggung utang perusahaan|Utang-utang marang aset resik NAYA Bio|NAYA - Utang jangka dawa perusahaan|Utang jangka cendhak NAYA Biosciences|Koefisien jangkoan perantara nayabiosciences.com
- data bathi lan kelipatan valuasi:
NAYA - Bathi resik|Bathi mangsa ngarep NAYA Biosciences|NAYA - Pangali P/E|Kapitalisasi marang proyeksi bathi NAYA Biosciences Inc|NAYA - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan NAYA Bio|NAYA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan NAYA Biosciences|NAYA - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan nayabiosciences.com|NAYA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep NAYA Biosciences
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:NAYA, nayabiosciences.com
To assess long-term risks, the investor utilizes the P/S ratio, calculated as the ratio of market capitalization to annual sales, which reflects the cost of each unit of revenue. When analyzing the price-to-sales chart, it should be noted that for NAYA Biosciences (NAYA), this metric is speculative in nature due to the lack of mass-market sales prior to the completion of clinical trials and the procurement of licenses.
Pesaing NAYA Biosciences
beigene.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S HALO (Halozyme)|Multiplikator P/S Revolution Medicines Inc RVMD|AAPG: Kapitalisasi marang pendapatan|Rega marang dodolan CG Oncology Therapeutics|URGN: Multiplikator P/S|bicara.com (BCAX) - Multiplikator P/S|Kapitalisasi marang pendapatan PSNL|ERAS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DCTH|Rasio rega marang pendapatan YMAB (Y-mAbs Corp)|Multiplikator P/S AURA (Aura Biosciences, Inc.)|Koefisien rega marang pendapatan Candel Therapeutics Inc. (CADL)|ARAY - Rasio rega marang pendapatan|Rega marang dodolan SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang pendapatan|CTOR - Koefisien rega marang pendapatan|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan protaratx.com (TARA)|Multiplikator P/S FATE|Koefisien rega marang pendapatan aadibio.com|Multiplikator P/S TCRX (TScan Therapeutics, Inc.)|Champions Oncology Inc (CSBR) - Rega marang dodolan|XBIT - Rasio rega marang pendapatan|CVM (CEL-SCI Corporation) - Rasio kapitalisasi marang pendapatan|OSTX: Multiplikator P/S|Kapitalisasi marang pendapatan radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator P/S|Rega marang dodolan Adlai Nortye Limited ANL|Rasio rega marang pendapatan Veru Inc. (VERU)|Koefisien rega marang pendapatan tempesttx.com|Rasio rega marang pendapatan Xilio Therapeutics XLO|RENB: Rasio kapitalisasi marang pendapatan|Mural Bio - Multiplikator P/S|KAPA - Multiplikator P/S|OKUR (onkuretherapeutics.com) - Kapitalisasi marang pendapatan|Rega marang dodolan CytoMed Therapeutics Limited (GDTC)|CRIS (Curis Inc.) - Multiplikator P/S|Multiplikator P/S Apollomics Corp|Multiplikator P/S THAR|Kapitalisasi marang pendapatan advanbiomed.com ADVB|Multiplikator P/S GNPX (Genprex, Inc.)|Multiplikator P/S Calidi Biotherapeutics Inc. CLDI|SBFM - Rasio rega marang pendapatan|XBIO (Xenetic Biosciences) - Rasio kapitalisasi marang pendapatan|SLRX: Multiplikator P/S|Kapitalisasi marang pendapatan Kitov Pharma|AONC (American Oncology Network Inc) - Multiplikator P/S|Rega marang dodolan beigene.com BGNE|Rasio rega marang pendapatan Checkpoint Therapeutics, Inc. (CKPT)|ELEV (elevationoncology.com) - Rasio kapitalisasi pasar marang pendapatan|iCAD - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IKNA|Notable Labs, Ltd. - Multiplikator P/S|Viracta Therapeutics (VIRX) - Kapitalisasi marang pendapatan|MOR (MorphoSys) - Kapitalisasi marang pendapatan|Ascentage Pharma Group International (AAPGV) - Multiplikator P/S
